Key result
Angiotensin system inhibitors linked to ~16% lower mortality versus other antihypertensives in metastatic RCC.
Why the study?
Does angiotensin system inhibitor use improve overall survival in patients with metastatic renal cell carcinoma?
Cohort (n=4,736)
Does angiotensin system inhibitor use improve overall survival in patients with metastatic renal cell carcinoma?
Effect estimate: HR 0.838
Absolute Event Rate: 26.68% vs 18.07%
p-value: p=0.0105
Angiotensin system inhibitor use is associated with improved overall survival in patients with metastatic renal cell carcinoma receiving VEGF-targeted therapy.
No takes yet. Share an insight, caveat, or question.
Associated with improved survival on VEGF therapy in metastatic renal cell carcinoma; leaves open need for randomized confirmation.
McKay et al. (2015) conducted a cohort in Metastatic Renal Cell Carcinoma (mRCC) (n=4,736). Angiotensin system inhibitors (ASI) vs. Other antihypertensive agents or no antihypertensive therapy was evaluated on Overall survival (OS) (HR 0.838, p=0.0105). Angiotensin system inhibitor use improved overall survival compared with other antihypertensive agents (HR 0.838; P=0.0105; 26.68 vs 18.07 months) in patients with metastatic renal cell carcinoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: